(Hypertension. 2001;37:936.)
© 2001 American Heart Association, Inc.
Scientific Contributions |
From the Specialized Center of Research in Hypertension Genetics, the Cardiovascular Center and Department of Internal Medicine, The University of Iowa, and Veterans Affairs Medical Center, Iowa City, Iowa.
Correspondence to William G. Haynes, MD, Department of Internal Medicine, University of Iowa, Iowa City, IA 52242. E-mail william-g-haynes{at}uiowa.edu
| Abstract |
|---|
|
|
|---|
Key Words: hormones sodium obesity hypertension, arterial sympathetic nervous system
| Introduction |
|---|
|
|
|---|
Intravenous leptin increases sympathetic nerve activity to interscapular brown adipose tissue (BAT).5 In addition, injection of leptin into the third cerebral ventricle activates sympathetic nerves to BAT.6 Intravenous leptin also increases sympathetic nerve activity to the kidneys, hind limbs, and adrenal glands in anesthetized rats.5
Chronic high-dose intravenous or intracarotid administration of leptin increases arterial pressure and heart rate in conscious rats.7 It is not known whether these effects are peripherally or centrally mediated because no difference was found between the pressor effect of intravenous versus carotid administration of leptin. Dunbar et al8 and Casto et al9 have shown that acute administration of high doses of leptin into the lateral ventricle transiently increases arterial pressure in anesthetized and conscious rats, respectively.
We hypothesized that leptin-induced increases in arterial pressure after long-term administration are due to a central neural action. To test this hypothesis, we administered leptin or vehicle into the third cerebral ventricle or jugular vein and recorded hemodynamic variables through radiotelemetry in conscious, lean, normotensive rats. Weight loss is known to decrease arterial pressure in both normotensive and hypertensive animals.10 11 Similar findings have been reported in humans.12 To control for the effects of weight loss on arterial pressure, we pair-fed vehicle-treated animals so that their food intake matched that of leptin-treated rats. Finally, the interactions between leptin and salt intake were also studied by feeding rats a low-salt or high-salt diet.
| Methods |
|---|
|
|
|---|
Procedures
Intracerebroventricular
Cannulation
Rats were anesthetized with sodium
pentobarbital (50 mg/kg, IP, Abbott Laboratories) and secured in a Kopf
900 stereotaxic instrument (David Kopf Instruments). A
23-gauge stainless steel guide catheter (20 mm in length) was
lowered 10 degrees from vertical into the third ventricle according to
standard stereotaxic procedures. The coordinates with
respect to bregma were -1.0 mm anteroposterior, +1.5 mm
lateral from the midline, and -9.0 mm dorsoventral from the
dura. At the end of the experiments, animals were euthanized and the
brains stained and fixed in 10% formalin. Methylene blue staining and
microtone slicing confirmed the correct placement of the
catheter.
Radiotelemetry
Immediately after cannulation of the third ventricle,
a midline laparotomy was performed. A radiotelemetry transducer (model
TA11PA-C40 or TL11 mol/L2-C50-PXT, Data Sciences Inc) was inserted and
glued into the exposed aorta. Rats were given postoperative antibiotics
(Penicillin G benzathine and G procaine in aqueous suspension, 30 000
UI IM; Phoenix Pharmaceuticals Inc) and placed in individual
Plexiglas cages. Measurements of systolic and
diastolic arterial pressure were recorded
continuously for 5 seconds every 8 minutes. These radiotelemetry
measurements were stored for later analyses with Dataquest
LabPro 3.01 software (Data Sciences Inc). Radiotelemetry data were
averaged over 24-hour intervals.
Osmotic Minipump Implantation
After a 2-week recovery period, rats were briefly
anesthetized with methohexital sodium (Brevital, 50 mg/kg IP).
Primed miniosmotic pumps (Alza) were connected through PE-050 tubes to
the intracerebroventricular catheters
or implanted into the right external jugular vein. The osmotic
minipumps were placed subcutaneously.
Air-Jet Stress
Rats were placed in Plexiglas holders, which
permitted only forward and backward movements, for 10 minutes before an
equal period of baseline measurements. Acute environmental stress
consisted of a jet of air directed to the neck through a tube located 4
to 6 cm from the rat and lasted 10 minutes. Arterial
pressure and heart rate were recorded for 5 seconds every minute.
With this protocol, pressor responses to 2 episodes of air-jet stress,
separated by 1 week, were closely correlated
(r=0.68;
P=0.001).
Study Design
After implantation of the radiotelemetry devices and
intracerebroventricular catheters,
there was a 1-week recovery period during which animals were left
undisturbed and had free access to regular rat chow and water. Daily
food intake and body weight were then recorded for a 1-week control
period and during treatment period in all groups. At the end of the
control period, osmotic minipumps were implanted and the regular rat
chow was switched to salt-restricted (0.13%, ICN Nutritional
Biochemicals) or salt-rich (4%, ICN) diets. Telemetry was recorded
continuously. Control animals were treated with vehicle and pair-fed to
the leptin-treated groups or allowed free access to food in each
protocol. At the end of each treatment period, cerebrospinal fluid
(CSF) and blood were drawn before a lethal injection of methohexital
sodium for measurement of leptin levels.
Intracerebroventricular
Administration
Two doses of leptin were given by
intracerebroventricular administration
to rats fed 0.13% salt diet: 200 ng/h and 1000 ng/h. In the low-dose
study, 200 ng/h of leptin (n=15) or vehicle (n=10) was administered by
osmotic minipumps (model 2002; infusion rate, 0.5 µL/h; total
capacity, 200 µL) for 2 weeks. In the high-dose study, osmotic
minipumps (model 2004; infusion rate, 0.25 µL/h; total capacity, 200
µL) were used to infuse 1000 ng/h of leptin (n=10) or vehicle (n=10)
for 28 days. In a subgroup of rats (n=5), high-dose leptin was
identically infused, but animals were euthanized after 14 days to
measure CSF levels of leptin. Free-fed rats (n=6) served as controls
for both low-dose and high-dose studies. Air-jet stress was applied
every 7 days.
An additional group of animals was treated with intracerebroventricular leptin at 1000 ng/h for 2 weeks and fed a 4% salt diet (n=10). Vehicle pair-fed (n=10) and free-fed animals (n=10) served as control animals.
Intravenous Administration
Leptin at 1000 ng/h (n=6), 18 000 ng/h (n=10) or
vehicle (n=6) was delivered by osmotic minipumps for 28 days.
Vehicle-treated animals pair-fed to rats treated with
intravenous leptin at 1000 and 18 000 ng/h groups were
also obtained (n=6 and 10, respectively). The higher dose was delivered
by model 2 ML4 minipump (infusion rate, 2.5 µL/h; total capacity, 2
mL). We reasoned that if 1000 ng/h given intravenously did
not alter arterial pressure, then the effects of the
intracerebroventricular administration
of 1000 ng/h of leptin could not be attributed to the possibility of
spillover into the systemic circulation. A free-fed group (n=10)
was also obtained. The 18 000 ng/h group was included as a positive
control; this dose has been previously shown to have
hemodynamic
effects.7
Analytical
Plasma and CSF murine leptin concentrations were
measured by radioimmunoassay (Linco Inc). Interassay coefficient of
variance in our laboratory is 2.7% at 1.18 ng/mL, and the sensitivity
is 0.2 ng/mL.
Data Analyses
All parameters were expressed as
mean±SEM of absolute change relative to the respective control
average. Differences between leptin and vehicle-treated rats were
assessed by repeated-measures ANOVA or by Students
t test. Statistical
analysis was performed with StatView 521+ software for
Macintosh (BrainPower Inc). A value of
P<0.05 was considered
statistically significant.
| Results |
|---|
|
|
|---|
|
Intracerebroventricular
Leptin at 1000 ng/h in Rats Fed Low-Salt Diet
Food intake decreased approximately equally in the
group given 1000 ng/h leptin and in the vehicle pair-fed groups and, to
a lesser degree, in the free-fed group
(Table 2 and
Figure 1). Body weight decreased substantially in
leptin-treated and vehicle pair-fed groups, whereas vehicle free-fed
rats gained weight
(Figure 1). Food intake and body weight started to return
toward baseline after 2 weeks of treatment. At 4 weeks, food intake in
leptin-treated and vehicle-treated animals was similar; however,
vehicle-treated free-fed animals were substantially heavier than
leptin-treated and vehicle-treated, pair-fed rats
(Table 2).
|
|
HR during the second week of treatment increased substantially in leptin-treated rats (+54±5 bpm), whereas it decreased in the pair-fed (-68±2 bpm, P<0.001 versus leptin) and free-fed (-12±1 bpm, P<0.001 versus leptin) groups (Table 2 and Figure 2). MAP increased in rats receiving leptin (+4±1 mm Hg) during the first week of treatment, in contrast to a reduction in MAP in pair-fed (-4±1 mm Hg, P<0.001 versus leptin) and in free-fed rats (-2±1 mm Hg, P<0.01 versus leptin) (Table 2 and Figure 2). However, MAP gradually decreased during the second week of leptin treatment, so that there was no difference between groups at 4 weeks (Table 2).
|
Intracerebroventricular
Leptin at 1000 ng/h in Rats Fed High-Salt Diet
Food intake and body weight decreased substantially in
the leptin-treated (1000 ng/h) and vehicle-treated, pair-fed groups,
whereas vehicle-treated, free-fed rats gained weight
(Table 3 and
Figure 3). The HR during the second week of treatment
increased substantially in leptin-treated rats (+53±2 bpm) and
slightly in the free-fed control rats (+8±3 bpm,
P<0.05 versus leptin).
Meanwhile, HR decreased in the pair-fed rats (-58±1 bpm,
P<0.001 versus leptin)
(Figure 4). MAP increased steadily in leptin-treated rats
(+3±1 mm Hg), whereas MAP decreased in pair-fed rats
(-6±1 mm Hg, P<0.01
versus leptin)
(Figure 4). MAP did not change in free-fed rats (-1±1
mm Hg, P=NS versus leptin)
(Figure 4).
|
|
|
Air-Jet Stress in Rats Treated With
Intracerebrovascular Leptin (1000 ng/h)
The MAP response to air-jet stress was greater in
leptin-treated animals on the low-salt diet compared with the pair-fed
control rats after 1 week of treatment, but there was no difference at
2 weeks
(Figure 5). The HR response to air-jet stress decreased in
the leptin group
(Figure 5).
|
Intravenous Leptin at 1000 and
18 000 ng/h in Rats Fed Low-Salt Diet
In a control study, intravenous
administration of 1000 ng/h of leptin did not decrease food intake or
body weight and did not alter MAP or HR
(Table 4).
|
Intravenous administration of 18 000 ng/h of leptin caused a sustained reduction in food intake and a transient decrease in body weight (Table 4). Similar effects were seen in the pair-fed control rats (Table 4). HR increased after leptin treatment, whereas pair-fed control rats showed bradycardia (Table 4). As with the highest intracerebroventricular dose, intravenous leptin at 18 000 ng/h prevented the depressor effect of weight loss (Table 4).
Leptin Concentration in CSF and Plasma
Neither CSF nor plasma concentrations of leptin were
different between rats treated with 200 ng/h ICV leptin or vehicle
(Table 5). In the group treated with 1000 ng/h of leptin for
2 weeks, the CSF leptin concentration increased markedly. At 4 weeks,
the CSF leptin concentration had fallen, almost back to control levels.
There was no significant difference in plasma leptin between animals
receiving intracerebroventricular
leptin or vehicle
(Table 5). In rats given
intracerebroventricular leptin and on a
high-salt diet, leptin CSF concentration at 2 weeks was also
substantially elevated
(Table 5). Leptin concentrations in the CSF did not differ
between rats treated with 1000 ng/h IV leptin or vehicle
(Table 5).
|
| Discussion |
|---|
|
|
|---|
In a control study, intracerebroventricular administration of leptin at 18 000 ng/h also caused weight loss and tachycardia and prevented the depressor effect of weight loss in low-saltfed animals. This observation corroborates the results of Shek et al7 and supports the biological activity of leptin as administered by osmotic minipump.
Leptin has been shown to cause sympathoactivation after intravenous or intracerebroventricular administration.5 8 Several peripheral actions of leptin have also been described that may alter arterial pressure. Human leptin but not murine or rat leptin has been shown to induce natriuresis and diuresis by acting locally in the rat kidney.15 16 In addition, leptin stimulates endothelial nitric oxidemediated vasorelaxation in vitro17 and in vivo.18 Leptin acutely increases insulin sensitivity.19 These peripheral effects of leptin may potentially decrease arterial pressure.
The mechanism by which leptin increased arterial pressure in our study probably reflects central activation of the sympathetic nervous system.5 8 Unequivocal evidence for sympathetic activation mediated by leptin could not be obtained from our experiments. Nevertheless, indirect evidence suggests the participation of sympathetic mechanisms to increase arterial pressure. First, a substantial dose-dependent increase in heart rate was observed in leptin-treated animals as opposed to bradycardia exhibited by the vehicle-treated, pair-fed control rats. Second, leptin-treated animals exhibited an enhanced pressor response during environmental stress. Finally, our group and others have reported that leptin administered into the cerebral ventricles of anesthetized rats increases sympathetic activity to the kidneys, adrenals, hind limbs, and BAT.5 8 In addition, Aizawa-Abe et al20 have shown that adrenergic antagonists prevent the pressor effect caused by human leptin overexpressed in the liver of transgenic mice.
Leptin CSF concentration was highest at 2 weeks and fell toward baseline at 4 weeks (Table 5). The pressor effect of leptin was proportional to the CSF concentration of leptin. Failure of the administration system or peptide inactivation might explain the decrease in CSF concentrations at 4 weeks. Whatever the mechanism, the decrease in arterial pressure as CSF leptin concentrations decreased strengthens rather than weakens the hypothesis that leptin acts in the CNS to increase arterial pressure.
Salt-sensitive hypertension develops in obese rats.21 Obesity is usually accompanied by hyperleptinemia. Therefore, we have studied the effects of a high-salt diet on the pressor responses of intracerebroventricular administration of leptin. Weight loss did not decrease arterial pressure to as great an extent in high-saltfed as compared with low-saltfed animals. We have shown that increases in arterial pressure were similar in leptin-treated rats fed a low-salt or a high-salt diet, indicating that leptin-dependent mechanisms in the central nervous system do not alter arterial pressure sensitivity to salt. This result suggests that leptin may not contribute to arterial pressure sensitivity to salt in hyperleptinemic obese rats.
Study Limitations
One limitation of our study is that the CSF
concentration of leptin that increased arterial pressure
was much higher than the usual concentration observed
physiologically. The CSF leptin concentration
in vehicle-treated, free-fed animals probably reflects the
physiological level in Sprague-Dawley rats.
However, obesity is associated with elevated leptin concentrations in
the CSF and
plasma,22 23 so
these results may be relevant to the pathophysiology of obesity-related
hypertension. Also, the use of leptin as a pharmacological agent for
therapy of obesity may result in similarly high CSF concentrations.
Another potential limitation is that recombinant murine leptin was used
rather than rat leptin. However, we demonstrated that murine leptin was
biologically active in rats, inhibiting appetite and decreasing body
weight.24
Conclusions
We have shown that local central nervous system
administration of leptin causes pressor and positive chronotropic
actions that probably are mediated through central sympathetic
mechanisms. The pressor effect of leptin appears to oppose the
hypotensive effect of food restriction. Finally, leptin does not appear
to increase salt sensitivity of arterial
pressure.
| Acknowledgments |
|---|
Received July 31, 2000; first decision August 31, 2000; accepted September 15, 2000.
| References |
|---|
|
|
|---|
2. Campfield LA, Smith FJ, Brun P. The OB protein (leptin): a link between adipose tissue mass and central neural networks. Horm Metab Res. 1996;28:619632.[Medline] [Order article via Infotrieve]
3.
Pelleymounter MA,
Cullen MJ, Baker MB, Hecht R, Winters D, Boone T, Collins F. Effects of
the obese gene product on body weight regulation in
ob/ob mice.
Science. 1995;269:540543.
4. Collins S, Kuhn CM, Petro AE, Swick AG, Chrunyk BA, Surwit RS. Role of leptin in fat regulation. Nature. 1996;380:677. Abstract.[Medline] [Order article via Infotrieve]
5. Haynes WG, Morgan DA, Walsh SA, Mark AL, Sivitz WI. Receptor-mediated regional sympathetic nerve activation by leptin. J Clin Invest. 1997;15:100:270278.
6. Haynes WG, Morgan DA, Walsh SA, Sivitz WI, Johnson AK, Mark AL. Sympathetic activation by leptin is mediated by the hypothalamus. FASEB J. 1998;12:A65. Abstract.
7.
Shek EW, Brands MW,
Hall JE. Chronic leptin infusion increases arterial
pressure. Hypertension. 1998;31:409414.
8. Dunbar JC, Hu Y, Lu H. Intracerebroventricular leptin increases lumbar and renal sympathetic nerve activity and blood pressure in normal rats. Diabetes. 1997;46:20402043.[Abstract]
9. Casto MR, VanNess JM, Overton JM. Effects of central leptin administration on blood pressure in normotensive rats. Neurosci Lett. 1998;246:2932.[Medline] [Order article via Infotrieve]
10. Young JB, Mullen D, Landsberg L. Caloric restriction lowers blood pressure in the spontaneously hypertensive rat. Metabolism. 1978;27:17111714.[Medline] [Order article via Infotrieve]
11.
Overton JM,
VanNess JM, Casto RM. Food restriction reduces sympathetic support of
blood pressure in spontaneously hypertensive rats.
J Nutr. 1997;127:655660.
12.
Scherrer U,
Nussberger J, Torriani S, Waeber B, Darioli R, Hofstetter JR, Brunner
HR. Effect of weight-reduction in moderately overweight patients on
recorded ambulatory blood-pressure and free cytosolic platelet
calcium. Circulation. 1991;83:552558.
13.
Halaas JL,
Gajiwalla KS, Maffei M, Cohen SL, Chait BT, Rabinowitz D, Lallone RL,
Burley SK, Friedman JM. Weight reducing effects of the plasma protein
encoded by the obese gene.
Science. 1995;269:543546.
14. Seeley RJ, van Dijk G, Campfield LA, Smith FJ, Burn P, Nelligan JA, Bell SM, Baskin DG, Woods SC, Schwartz MW. Intraventricular leptin reduces food intake and body weight of lean rats but not obese Zucker rats. Horm Metab Res. 1996;28:664668.[Medline] [Order article via Infotrieve]
15.
Jackson EK, Li P.
Human leptin has natriuretic activity in the rat.
Am J Physiol. 1997;272:F333F338.
16. Jackson EK, Herzer WA. A comparison of the natriuretic/diuretic effects of rat vs human leptin in the rat. Am J Physiol. 1999;277:F761F765.
17. Lembo G, Vecchione C, Fratta L, Marino G, Trimarco V, dAmati G, Trimarco B. Leptin induces direct vasodilation through distinct endothelial mechanisms. Diabetes. 2000;49:293297.[Abstract]
18. Fruhbeck G. Pivotal role of nitric oxide in the control of blood pressure after leptin administration. Diabetes. 1999;48:903908.[Abstract]
19.
Sivitz WI, Walsh
SA, Morgan DA, Thomas MJ, Haynes WG. Effects of leptin on insulin
sensitivity in normal rats.
Endocrinology. 1997;138:33953401.
20. Aizawa-Abe M, Ogawa Y, Masuzaki H, Ebihara K, Satoh N, Iwai H, Matsuoka N, Hayashi T, Hosoda K, Inoue G, Yoshimasa Y, Nakao K. Pathophysiological role of leptin in obesity-related hypertension. J Clin Invest. 2000;105:12431252.[Medline] [Order article via Infotrieve]
21. Suzuki H, Ikenaga H, Hayashida T, Otsuka K, Kanno Y, Ohno Y, Ikeda H, Saruta T. Sodium balance and hypertension in obese and fatty rats. Kidney Int. 1996;55:S150S153.
22. Caro JF, Kolaczynski JW, Nyce MR, Ohannesian JP, Opentanova I, Goldman WH, Lynn RB, Zhang P-L, Sinha MK, Considine RV. Decreased cerebrospinal-fluid/serum leptin ratio in obesity: a possible mechanism for leptin resistance. Lancet. 1996;348:159161.[Medline] [Order article via Infotrieve]
23.
Considine RV,
Sinha MK, Heiman ML, Kriauciunas A, Stephens TW, Nyce MR, Ohannesian
JP, Marco CC, McKee LJ, Bauer TL, Caro JF. Serum immunoreactive leptin
concentrations in normal weight and obese humans.
N Engl J Med. 1996;334:292295.
24.
Haynes WG, Sivitz
WI, Morgan DA, Walsh SA, Mark AL. Sympathetic and cardiorenal actions
of leptin. Hypertension. 1997;30:619623.
This article has been cited by other articles:
![]() |
E. J. Belin de Chantemele, K. Muta, J. Mintz, M. L. Tremblay, M. B. Marrero, D. J. Fulton, and D. W. Stepp Protein Tyrosine Phosphatase 1B, a Major Regulator of Leptin-Mediated Control of Cardiovascular Function Circulation, September 1, 2009; 120(9): 753 - 763. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Galletti, L. D'Elia, G. Barba, A. Siani, F. P. Cappuccio, E. Farinaro, R. Iacone, O. Russo, D. De Palma, R. Ippolito, et al. High-Circulating Leptin Levels Are Associated with Greater Risk of Hypertension in Men Independently of Body Mass and Insulin Resistance: Results of an Eight-Year Follow-Up Study J. Clin. Endocrinol. Metab., October 1, 2008; 93(10): 3922 - 3926. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. K. Koh, S. M. Park, and M. J. Quon Leptin and Cardiovascular Disease: Response to Therapeutic Interventions Circulation, June 24, 2008; 117(25): 3238 - 3249. [Full Text] [PDF] |
||||
![]() |
R. Yang and L. A. Barouch Leptin Signaling and Obesity: Cardiovascular Consequences Circ. Res., September 14, 2007; 101(6): 545 - 559. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Katagiri, T. Yamada, and Y. Oka Adiposity and Cardiovascular Disorders: Disturbance of the Regulatory System Consisting of Humoral and Neuronal Signals Circ. Res., July 6, 2007; 101(1): 27 - 39. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Rahmouni and D. A. Morgan Hypothalamic Arcuate Nucleus Mediates the Sympathetic and Arterial Pressure Responses to Leptin Hypertension, March 1, 2007; 49(3): 647 - 652. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. C. Okere, M. P. Chandler, T. A. McElfresh, J. H. Rennison, V. Sharov, H. N. Sabbah, K.-Y. Tserng, B. D. Hoit, P. Ernsberger, M. E. Young, et al. Differential effects of saturated and unsaturated fatty acid diets on cardiomyocyte apoptosis, adipose distribution, and serum leptin Am J Physiol Heart Circ Physiol, July 1, 2006; 291(1): H38 - H44. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Bjursell, A.-K. Gerdin, K. Ploj, D. Svensson, L. Svensson, J. Oscarsson, M. Snaith, J. Tornell, and M. Bohlooly-Y Melanin-Concentrating Hormone Receptor 1 Deficiency Increases Insulin Sensitivity in Obese Leptin-Deficient Mice Without Affecting Body Weight Diabetes, March 1, 2006; 55(3): 725 - 733. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. S. Tallam, D. E. Stec, M. A. Willis, A. A. da Silva, and J. E. Hall Melanocortin-4 Receptor-Deficient Mice Are Not Hypertensive or Salt-Sensitive Despite Obesity, Hyperinsulinemia, and Hyperleptinemia Hypertension, August 1, 2005; 46(2): 326 - 332. [Abstract] [Full Text] [PDF] |
||||
![]() |
F.-P. Xu, M.-S. Chen, Y.-Z. Wang, Q. Yi, S.-B. Lin, A. F. Chen, and J.-D. Luo Leptin Induces Hypertrophy via Endothelin-1-Reactive Oxygen Species Pathway in Cultured Neonatal Rat Cardiomyocytes Circulation, September 7, 2004; 110(10): 1269 - 1275. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. S. Gopalakrishnan, D. S. Gardner, S. M. Rhind, M. T. Rae, C. E. Kyle, A. N. Brooks, R. M. Walker, M. M. Ramsay, D. H. Keisler, T. Stephenson, et al. Programming of adult cardiovascular function after early maternal undernutrition in sheep Am J Physiol Regulatory Integrative Comp Physiol, July 1, 2004; 287(1): R12 - R20. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z.-H. Zhang and R. B. Felder Melanocortin receptors mediate the excitatory effects of blood-borne murine leptin on hypothalamic paraventricular neurons in rat Am J Physiol Regulatory Integrative Comp Physiol, February 1, 2004; 286(2): R303 - R310. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Rahmouni and W. G. Haynes Leptin and the Cardiovascular System Recent Prog. Horm. Res., January 1, 2004; 59(1): 225 - 244. [Abstract] [Full Text] |
||||
![]() |
B. E. Levin, A. A. Dunn-Meynell, and W. A. Banks Obesity-prone rats have normal blood-brain barrier transport but defective central leptin signaling before obesity onset Am J Physiol Regulatory Integrative Comp Physiol, January 1, 2004; 286(1): R143 - R150. [Abstract] [Full Text] |
||||
![]() |
A. D. Dobrian, S. D. Schriver, T. Lynch, and R. L. Prewitt Effect of salt on hypertension and oxidative stress in a rat model of diet-induced obesity Am J Physiol Renal Physiol, October 1, 2003; 285(4): F619 - F628. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. J. Marsh, M. A.P. Fontes, S. Killinger, D. B. Pawlak, J. W. Polson, and R. A.L. Dampney Cardiovascular Responses Evoked by Leptin Acting on Neurons in the Ventromedial and Dorsomedial Hypothalamus Hypertension, October 1, 2003; 42(4): 488 - 493. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. J. Lyon, R. E. Law, and W. A. Hsueh Minireview: Adiposity, Inflammation, and Atherogenesis Endocrinology, June 1, 2003; 144(6): 2195 - 2200. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Shirasaka, M. Takasaki, and H. Kannan Cardiovascular effects of leptin and orexins Am J Physiol Regulatory Integrative Comp Physiol, March 1, 2003; 284(3): R639 - R651. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Fortuno, A. Rodriguez, J. Gomez-Ambrosi, P. Muniz, J. Salvador, J. Diez, and G. Fruhbeck Leptin Inhibits Angiotensin II-Induced Intracellular Calcium Increase and Vasoconstriction in the Rat Aorta Endocrinology, September 1, 2002; 143(9): 3555 - 3560. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Carlyle, O. B. Jones, J. J. Kuo, and J. E. Hall Chronic Cardiovascular and Renal Actions of Leptin: Role of Adrenergic Activity Hypertension, February 1, 2002; 39(2): 496 - 501. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. J. Swoap Altered leptin signaling is sufficient, but not required, for hypotension associated with caloric restriction Am J Physiol Heart Circ Physiol, December 1, 2001; 281(6): H2473 - H2479. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. L. Mitchell, D. A. Morgan, M. L.G. Correia, A. L. Mark, W. I. Sivitz, and W. G. Haynes Does Leptin Stimulate Nitric Oxide to Oppose the Effects of Sympathetic Activation? Hypertension, November 1, 2001; 38(5): 1081 - 1086. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. L.G. Correia, D. A. Morgan, J. L. Mitchell, W. I. Sivitz, A. L. Mark, and W. G. Haynes Role of Corticotrophin-Releasing Factor in Effects of Leptin on Sympathetic Nerve Activity and Arterial Pressure Hypertension, September 1, 2001; 38(3): 384 - 388. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Hypertension Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2001 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |